Background
==========

Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver injury in many countries in the world \[[@B1],[@B2]\], and epidemiological studies have shown that its prevalence ranges from 17% to 33% of the general population. NAFLD represents a spectrum of conditions that are histologically characterized by macrovesicular hepatic steatosis, and the diagnosis is made in patients who have not consumed alcohol in amounts sufficient to be considered to be harmful to the liver. The histological changes range over a wide spectrum, extending from simple steatosis, which is generally non-progressive, to nonalcoholic steatohepatitis (NASH), liver cirrhosis, liver failure, and sometimes even hepatocellular carcinoma \[[@B3],[@B4]\].

Genetic factors as well as environmental factors are important to the development of NAFLD \[[@B5]-[@B8]\], and the gene for peroxisome proliferator-activated receptor γ coactivator 1α (*PPARGC1A*) is a candidate gene for susceptibility to NAFLD, since it is involved in insulin resistance, mitochondrial biogenesis, and oxidative phosphorylation, which are key factors in the development of NAFLD \[[@B9]-[@B11]\]. Recent evidence also implicates *PPARGC1A*in the homeostatic control of systemic energy metabolism, and *PPARGC1A*knockout mice have been reported to develop hepatic steatosis due to a combination of reduced mitochondrial respiratory capacity and increased expression of lipogenic genes \[[@B12]\]. Single nucleotide polymorphisms (SNPs) are useful tools in the search for genetic factors responsible for disease and are being intensively investigated in various common diseases, such as obesity, diabetes, and hypertension. Expression of *PPARGC1A*has been reported to be associated with metabolic factors, such as type 2 diabetes, hypertension, obesity \[[@B13]-[@B18]\].

In this study we investigated associations between SNPs of *PPARGC1A*and NAFLD in the Japanese subjects.

Methods
=======

Subjects
--------

A total of 115 Japanese NAFLD patients, 65 with NASH and 50 with simple steatosis, and 441 healthy control subjects were recruited to participate in this study at Yokohama City University Hospital. All control subjects were confirmed to have normal liver function, not to have viral hepatitis, and not to be alcoholics. The control subjects all had a BMI \< 25 kg/m^2^, normal fasting glucose (\<110 mg/dl), serum triglycerides (\<150 mg/dl), and serum HDL cholesterol (\>40 mg/dl) levels, and normal systolic (\<130 mmHg) and diastolic blood pressure (\<85 mmHg). Liver biopsy was performed in all 115 NAFLD patients, and the liver biopsy tissue obtained was stained with hematoxylin-eosin, reticulin stain, and Masson trichrome stain. The histological criterion used to make the diagnosis of NAFLD was the presence of macrovesicular fatty change in hepatocytes with displacement of the nucleus to the edge of the cell \[[@B19]\]. When more than 5% of hepatocytes were affected by macrovesicular steatosis, the patient was diagnosed as having either steatosis or steatohepatitis. The criteria used to make the diagnosis of steatohepatitis were the presence of lobular inflammation and the presence of either ballooning cells or perisinusoidal/pericellular fibrosis in zone 3 of the hepatic acinus, in addition to steatosis \[[@B20],[@B21]\]. Patients with any of the following diseases were excluded from participation in this study: infectious hepatitis (chronic hepatitis C infection or concurrent active hepatitis B virus), autoimmune hepatitis, primary biliary cirrhosis (PBC), sclerosing cholangitis, hemochromatosis, α1-antitrypsin deficiency, Wilson\'s disease, drug-induced hepatitis, and alcoholic hepatitis, and heavy alcohol consumers (current or past daily consumption of more than 20 g alcohol per day). No patients had clinical evidence of hepatic decompensation, such as hepatic encephalopathy, ascites, variceal bleeding, or a serum billirubin level greater than twice the upper limit of normal.

Written informed consent was obtained from all subjects before their entry into this study. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the Research Committee of Yokohama City Hospital.

Physical and laboratory evaluation
----------------------------------

The body weight and height of the patients were measured with a calibrated scale after requesting them to remove their shoes and any heavy clothing. A venous blood sample was obtained from the patients after an overnight fast (12 hours) to measure their serum AST, ALT, glucose, immunoreactive insulin (IRI), hemoglobin A1c (HbA1c), total cholesterol, HDL cholesterol, and triglyceride levels. All laboratory biochemical parameters were measured with a conventional automated analyzer. Visceral fat area (VFA) and subcutaneous fat area (SFA) were measured by computed tomography (CT).

DNA preparation and SNP genotyping
----------------------------------

Genomic DNA was prepared from each blood sample by using a commercial genomic DNA extraction kit (TALENT s.r.l., Trieste, Italy). The *PPARGC1A*SNPs were selected from the IMS-JST (Institute of Medical Science-Japan Science and Technology Agency) SNP database \[[@B22]\]. We selected the 15 SNPs with a minor allele frequency greater than 0.2 and whose expected allele frequencies did not widely diverge from Hardy-Weinberg equilibrium (*p*\> 0.001). Invader probes (Third Wave Technologies, Madison, WI) were synthesized for these SNPs, and the SNPs were genotyped in the cases and controls by a combination of multiplex PCR and the Invader assay, as described previously \[[@B23]\].

Real-time RT-PCR for measurement of PPARGCA1 mRNA expression
------------------------------------------------------------

Total RNA was isolated from samples of liver biopsy specimens by using an RNeasy Mini Kit (Quiagen, Hilden, Germany) according to the manufacturer\'s instructions. The protocol included a DNase treatment step to remove genomic DNA. The RNA was assessed quantitatively by measuring relative absorbance at 260 nm and 280 nm, and qualitatively by ethidium bromide agarose-gel electrophoresis. Reverse transcription to produce cDNA was performed by using a TaqMan Reverse Transcription Reagents (Applied Biosystems, Foster City, CA, USA), according to the manufacturer\'s instructions. The reaction mixtures (100 μl) contained 2.5 μg of total RNA, and after allowing the reaction to proceed for 50 minutes at 48°C, the reverse transcriptase was inactivated by heating the samples to 95°C for 5 minutes.

Real-time quantitative RT-PCR was performed in triplicate by using an ABI Prism 7700 sequence detection system (Applied Biosystems, Foster City, CA, USA) and SYBR Green PCR Master Mix according to the manufacturer\'s protocol. The following primers were used: *PPARGC1A*(F, 5\'-TCTGACGTGACCATGGTGTT-3\'; R, 5\'-CATTCCAGGGACTCCACACT-3\'). The primers were designed with Primer Express software (Applied Biosystems, Foster City, CA, USA) based on the sequence data obtained from the GenBank database. β-actin (Applied Biosystems, Foster City, CA, USA) was used as a reference; i.e., each sample was normalized on the basis of its β-actin content. Thermal cycling was performed as follows: initial denaturation at 95°C for 10 minutes, followed by 40 cycles of 95°C for 15seconds and 60°C for 1 minute.

Statistical analysis
--------------------

For each case-control study, the frequencies of the genotypes or the alleles were compared between cases and controls in three different modes by means of the χ^2^test. In the first mode (allele frequency mode), allele frequencies were compared between cases and controls by means of a 2 × 2 contingency table. In the second mode (recessive mode), the frequencies of the subjects who were homozygous for allele 1 were compared with the rest by means of a 2 × 2 contingency table, while in the third mode (dominant mode) the frequencies of the subjects who had allele 1 (allele 1 homozygotes and heterozygotes) were compared with the rest by means of a 2 × 2 contingency table. The odds ratio (OR) and its 95% confidence interval (CI) were calculated by Woolf\'s method. Conformity to the Hardy-Weinberg equilibrium was assessed by the χ^2^test \[[@B24]\]. Haplotype blocks were calculated using Haploview 3.2 software \[[@B25]\]. Physical and laboratory data are reported as means ± standard deviation (SD).

Results
=======

Case-control association study
------------------------------

The characteristics of NAFLD groups and control group are compared in Table [1](#T1){ref-type="table"}. We selected the 15 SNPs of the *PPARG1A*gene in the IMS-JST SNP database that had a minor allele frequency greater than 0.2. The information on SNP location has been added in Table [2](#T2){ref-type="table"} and Fig. [1](#F1){ref-type="fig"}. The rs2290602 SNP had the lowest *p*value in the dominant mode (*p*= 0.00095, Table [2](#T2){ref-type="table"}), and rs2290602 was significantly associated with NAFLD even when the most conservative Bonferroni\'s correction was applied (*p*= 0.00095 × 15 × 3 = 0.04275). The OR (95% CI) was 2.73 (1.48 -- 5.06) in the dominant mode, and thus the relative risk of developing NAFLD of the subjects with the T allele was 2.73 fold higher than among the subjects without the T allele. All SNPs except rs2290602 were in Hardy-Weinberg equilibrium (*p*\> 0.1). The departure of rs2290602 from the Hardy-Weinberg equilibrium was detected in the NAFLD group (*p*= 0.02), because this SNP is associated with NAFLD and the cases were selected for the phenotype. Case may be biased compared to the general population. Thus, it is not unexpected that case was not in Hardy-Weinberg equilibrium. Linkage disequilibrium (LD) analysis revealed the presence of two blocks in the *PPARG1A*gene. SNP rs2290602 and 11 other SNPs (rs2290604, rs3774907, rs3774908, rs2290603, rs2970849, rs2932968, rs3755863, rs3736265, rs3774920, rs768695, and rs3774923) were in the same block (Fig. [1](#F1){ref-type="fig"}).

###### 

Characteristics of the NAFLD patients and control subjects.

                                    Control        NAFLD           *P*-value
  --------------------------------- -------------- --------------- -----------
  Men/Women                         112/329        51/64           
  Age (years)                       47.4 ± 15.9    49.6 ± 15.1     0.20
  BMI (kg/m^2^)                     21.2 ± 2.2     27.4 ± 5.3      \<0.0001
  FBS (mg/dL)                       90.4 ± 7.4     117.2 ± 32.0    \<0.0001
  HbA1c (%)                         5.1 ± 0.6      5.8 ± 1.3       \<0.0001
  Total Cholesterol (mg/dL)         200.9 ± 33.4   211.7 ± 36.5    0.0027
  Triglycerides (mg/dL)             72.2 ± 27.6    168.9 ± 110.7   \<0.0001
  HDL cholesterol (mg/dL)           68.1 ± 13.9    52.9 ± 20.9     \<0.0001
  Systolic blood pressure (mmHg)    110.5 ± 9.9    124.1 ± 14.8    \<0.0001
  Diastolic blood pressure (mmHg)   69.2 ± 7.3     76.8 ± 11.3     \<0.0001
  AST (IU/L)                        20.1 ± 6.3     44.4 ± 26.3     \<0.0001
  ALT (IU/L)                        15.7 ± 6.5     70.4 ± 53.6     \<0.0001

Data are means ± SD.

###### 

Genotype frequencies and association tests of SNPs PPARGC1A gene using NAFLD and control

  Rs number   Location            allele1/allele2   NAFLD   Control   Allele frequency mode   Recessive mode   Dominant mode                                                                                                    
  ----------- ------------------- ----------------- ------- --------- ----------------------- ---------------- --------------- ----- ----- -------- --------------------- ----- -------- --------------------- ------ --------- ---------------------
  rs3774902   Intron 1 +745       T/C               46      49        19                      207              170             63    1.6   0.2008   0.82 (0.61 -- 1.11)   1.6   0.2010   0.76 (0.50 -- 1.16)   0.4    0.52917   0.84 (0.48 -- 1.46)
  rs2970871   Intron 1 +945       A/G               31      64        19                      121              212             107   1.0   0.3225   1.16 (0.87 -- 1.55)   0.0   0.9478   0.98 (0.62 -- 1.56)   3.0    0.08241   1.61 (0.94 -- 2.75)
  rs2970876   Intron 1 +2908      C/T               38      55        22                      109              226             102   2.8   0.0964   1.28 (0.96 -- 1.72)   3.1   0.0804   1.49 (0.95 -- 2.32)   0.9    0.33573   1.29 (0.77 -- 2.15)
  rs2290604   Intron 4 +848       A/G               77      33        3                       261              159             21    3.2   0.0716   1.42 (0.97 -- 2.07)   3.0   0.0815   1.48 (0.95 -- 2.29)   1.0    0.32629   1.83 (0.54 -- 6.26)
  rs3774907   Intron 5 +161       T/C               75      35        3                       280              138             21    0.6   0.4292   1.16 (0.80 -- 1.69)   0.3   0.6083   1.12 (0.72 -- 1.73)   1.0    0.32239   1.84 (0.54 -- 6.29)
  rs3774908   Intron 5 +1089      T/C               79      33        3                       261              158             21    3.6   0.0580   1.44 (0.99 -- 2.10)   3.4   0.0661   1.51 (0.97 -- 2.33)   1.0    0.30970   1.87 (0.55 -- 6.39)
  rs2290603   Intron 5 +3590      A/G               75      35        4                       264              154             19    1.0   0.3075   1.21 (0.84 -- 1.75)   1.1   0.2933   1.26 (0.82 -- 1.94)   0.2    0.68996   1.25 (0.42 -- 3.75)
  rs2290602   Intron 7 +171       T/G               34      67        13                      99               222             113   8.5   0.0036   1.55 (1.15 -- 2.08)   2.4   0.1201   1.44 (0.91 -- 2.28)   10.9   0.00095   2.73 (1.48 -- 5.06)
  rs2970849   Intron 7 +8096      A/G               68      42        5                       232              173             34    2.2   0.1385   1.30 (0.92 -- 1.82)   1.4   0.2287   1.29 (0.85 -- 1.96)   1.6    0.20492   1.85 (0.71 -- 4.83)
  rs2932968   Intron 7 +8494      T/C               74      36        4                       262              157             21    1.2   0.2809   1.22 (0.85 -- 1.76)   1.1   0.2959   1.26 (0.82 -- 1.93)   0.3    0.56233   1.38 (0.46 -- 4.10)
  rs3755863   Exon 8 +707 (T/T)   G/A               32      60        23                      82               222             135   7.3   0.0070   1.49 (1.11 -- 2.00)   4.7   0.0308   1.68 (1.05 -- 2.69)   5.2    0.02301   1.78 (1.08 -- 2.93)
  rs3736265   Exon 9 +42 (M/T)    A/G               81      30        3                       261              158             20    5.0   0.0259   1.55 (1.05 -- 2.29)   5.2   0.0231   1.67 (1.07 -- 2.62)   0.8    0.35922   1.77 (0.52 -- 6.05)
  rs3774920   Intron 10 +1732     A/G               79      32        3                       263              157             21    3.8   0.0528   1.46 (0.99 -- 2.14)   3.6   0.0587   1.53 (0.98 -- 2.37)   1.0    0.31886   1.85 (0.54 -- 6.31)
  rs768695    Intron 12 +4535     T/C               69      35        9                       229              184             27    1.2   0.2737   1.21 (0.86 -- 1.70)   2.9   0.0863   1.44 (0.95 -- 2.20)   0.5    0.48225   0.76 (0.34 -- 1.66)
  rs3774923   Exon 13 +2485       A/G               82      30        3                       263              157             20    5.0   0.0256   1.55 (1.05 -- 2.29)   5.2   0.0232   1.67 (1.07 -- 2.61)   0.9    0.35349   1.78 (0.52 -- 6.09)

^a^OR; odds ratio,

![**LD mapping around the PPARGC1A gene**. LD coefficients (d) were calculated for every pair of *PPARGC1A*SNPs. LD coefficients (D\') were calculated for every pair of SNPs and are shown as the strand of the LD blocks. The minor allele frequencies of all SNPs used in this analysis were \>20%. Each SNP is labeled with its rs number.](1471-230X-8-27-1){#F1}

Next, we divided the NAFLD group into the NASH and the steatosis group and used rs2290602 to perform case-control association studies. Although it was not conclusive because of the small number of data, the frequency of T allele was significantly higher in the NASH group than in the control group (*p*= 0.00093, allele frequency mode). When the frequency of the T allele in the NASH group was compared to its frequency in the steatosis group, its frequency was found to tend to be higher than in the steatosis group (*p*= 0.09). Thus, rs2290602 was significantly more closely associated with NASH than with simple steatosis (Table [3](#T3){ref-type="table"}).

###### 

Results of testing for differences in SNP rs2290602 frequency between NAFLD group and control group, NASH group and contol group, NASH group and simple steatosis group.

                              NAFLD   Control   Allele frequency mode   Recessive mode   Dominant mode                                                                                                      
  --------------------------- ------- --------- ----------------------- ---------------- --------------- ----- ----- --------- --------------------- ----- --------- --------------------- ------ --------- ---------------------
  NAFLD vs. Control           34      67        13                      99               222             113   1.6   0.00363   1.55 (1.15 -- 2.08)   2.4   0.12008   1.44 (0.91 -- 2.28)   10.9   0.00095   2.73 (1.48 -- 5.06)
  NASH vs. Control            24      34        6                       99               222             113   1.0   0.00093   1.90 (1.29 -- 2.79)   6.5   0.01097   2.03 (1.17 -- 3.53)   8.5    0.00352   3.40 (1.43 -- 8.10)
  NASH vs. simple steatosis   24      34        6                       10               33              7     2.8   0.09168   1.58 (0.93 -- 2.69)   4.1   0.04270   2.40 (1.02 -- 5.66)   0.6    0.44076   1.57 (0.49 -- 5.02)

To investigate whether the genotype of rs2290602 SNP were associated with the clinical parameters, we compared age, BMI, and the fasting plasma glucose, immunoreacrive insulin, HbA1c, total cholesterol, triglyceride, HDL cholesterol, AST, ALT, VFA, and SFA between the NAFLD patients with different genotypes (GG vs. GT + TT, or TT vs. GT + GG) by Student\'s *t*-test. The results showed that serum AST and ALT values of the NAFLD patients with the TT allele were significantly higher than those of the NAFLD patients with the GT or GG allele at SNP rs2290602 (Table [4](#T4){ref-type="table"}). When the subjects were limited to the NASH patients, the serum AST and ALT values were also significantly higher in the TT genotype group than in the GT group or GG group at SNP rs2290602 (*p*= 0.0177, *p*= 0.0140, respectively).

###### 

Comparison between various quantitative phenotypes in groups of NAFLD patients with different SNP genotypes at rs2290602

                              GG              GT+TT           p value   GG+GT           TT              p value
  --------------------------- --------------- --------------- --------- --------------- --------------- ---------
  N                           14              101                       80              35              
  Age (years)                 48.5 + 18.5     49.5 + 14.7     0.8303    48.4 + 14.4     51.7 + 16.4     0.2913
  BMI (kg/m2)                 27.3 + 7.2      27.2 + 4.8      0.9194    27.0 + 5.1      27.6 + 4.9      0.5581
  FBS (mg/dl)                 118.5 + 26.3    117.3 + 32.9    0.8929    116.8 + 32.0    118.7 + 32.8    0.7791
  IRI (ul/ml)                 13.6 + 6.2      13.7 + 8.9      0.9778    12.9 + 6.9      15.4 + 11.6     0.1865
  HbA1c (%)                   5.39 + 1.26     5.88 + 1.26     0.1890    5.83 + 1.28     5.80 + 1.23     0.9138
  Total cholesterol (mg/dl)   219.1 + 35.7    213.1 + 39.3    0.6017    214.7 + 39.5    211.6 + 37.5    0.6978
  HDL cholesterol (mg/dl)     50.6 + 10.0     53.3 + 22.0     0.6709    51.2 + 16.2     57.0 + 29.1     0.1800
  Triglycerides (mg/dl)       144.9 + 53.7    172.1 + 116.4   0.4102    159.1 + 70.4    192.2 + 172.3   0.1469
  AST (U/ml)                  35.0 + 12.2     45.8 + 27.5     0.1660    40.4 + 21.3     54.5 + 34.1     0.0085
  ALT (U/ml)                  50.4 + 27.2     73.4 + 55.7     0.1462    62.7 + 37.7     89.9 + 76.9     0.0127
  VFA (cm2)                   129.3 + 32.9    135.8 + 50.0    0.7585    135.4 + 47.4    134.9 + 51.3    0.9703
  SFA (cm2)                   274.6 + 148.9   229.4 + 116.8   0.3821    235.4 + 123.8   230.4 + 114.2   0.8709

Data are shown as means ± SD. VFA: visceral fat area, SFA: subcutaneous fat area, AST: aspartate aminotransferase, ALT: alanine aminotransferase, FBS: fasting blood sugar, IRI: Immunoreactive insulin,

mRNA expression of PPARGC1A in the liver
----------------------------------------

Expression of *PPARGC1A*mRNA in the liver biopsy specimens of NAFLD patients was evaluated by real-time RT-PCR. The results obtained by real-time RT-PCR in the GG or GT group (n = 10) were compared with the results in the TT group (n = 8) at SNP rs2290602. As shown in Fig. [2](#F2){ref-type="fig"}, the expression of *PPARGC1A*mRNA transcripts in the liver was significantly lower in the TT group than in the GG or GT group (p = 0.0454).

![**The expression of mRNA for *PPARGC1A*in the liver**. Significant difference in intrahepatic mRNA expression of *PPARGC1A*between the TT group (n = 8) and the GG or GT group (n = 10) at SNP rs2290602 (p = 0.0454).](1471-230X-8-27-2){#F2}

Discussion
==========

Genetic factors are important to the development of NAFLD, and recent advantages in SNP genotyping methods have enabled the detection of genetic the variations associated with increased susceptibility to NAFLD. There have been a few reports of genetic variations that are associated with NAFLD, and they have been in the genes for TNF receptor 2 (TNFR-2), TNF-α, micorosomal triglyceride transfer protein (MTP), and methylenetetrahydrofolate reductase (MTHFR) genes \[[@B6],[@B7],[@B26]\]. All of these genes are related to inflammation, lipid metabolism, and oxidation. We examined the 15 SNPs in *PPARGC1A*and found that rs2290602 was significantly associated with NAFLD, especially with NASH, and the frequency of the T allele of rs2290602 was significantly higher in the NASH patients than in the control subjects. We also found that intrahepatic *PPARGC1A*mRNA expression was significantly lower in the TT group than in the GG or GT group at SNP rs2290602.

*PPARGC1A*interacts with peroxisome proliferators-activated receptors (PPARs) and has various functions, including as integrator of the molecular regulatory circuitry involved in the transcriptional control of cellular energy metabolism, including mitochondrial function and biogenesis \[[@B27],[@B28]\], and regulation of gene expression involved in lipid and glucose metabolism. The *PPARGC1A*Gly482Ser polymorphism is also associated with obesity, hypertension, and diabetes \[[@B14]-[@B18],[@B29]\]. NAFLD is often accompanied by obesity, hypertriglyceridemia, type 2 diabetes, and insulin resistance \[[@B30]\], and *PPARGC1A*knockout mice develop hepatic steatosis \[[@B12]\]. Thus, variations in rs2290602 in the *PPARGC1A*gene would be expected to affect lipid and glucose metabolism, and result in the development of NAFLD and NASH.

Recent evidence also implicates *PPARGC1A*in the homeostatic control of systemic energy metabolism, and *PPARGC1A*has been shown to regulate several key hepatic gluconeogenic genes \[[@B31]-[@B34]\]. Recent studies have also shown altered expression of *PPARGC1A*and downstream mitochondrial target pathways in the skeletal muscle of humans with insulin resistance and diabetes \[[@B35]-[@B37]\].

This study had a limitation in regard to the control subjects. The number of the patients was too small for a polymorphism study. Although none of the control subjects had abnormal liver function or was obese, we cannot completely rule out the possibility that the control group included patients with mild steatosis, since we did not perform liver biopsies in the control subjects.

Conclusion
==========

In conclusion, this is the first study to demonstrate a significant association between genetic variations in *PPARGC1A*and NAFLD. This finding suggested that *PPARGC1A*polymorphism and lower expression of *PPARGC1A*mRNA in the liver are an important genetic contribution to the etiology of NAFLD.
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